Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Breast Neoplasms 2Renal Insufficiency 1Prostatic Neoplasms 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Renal Cell 1Carcinoma, Medullary 1Burkitt Lymphoma 1Breast Carcinoma In Situ 1Brain Neoplasms 1Blood Protein Disorders 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Advanced Cancer 1

Interventions

Nivolumab 20Ipilimumab 10Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Cancer × Ranitidine × Clear all
NCT01287520 2019-02-25

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
41 enrolled 28 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡